Genvor issues 200,000 shares to convert $100K owed

The issued shares represented conversion of $100,000 in payables under the scientific advisor agreement and the company's restructured compensation package.

Available on EDGAR 11/03/2026 - 12:53 PM EST Accepted by SEC EDGAR 11/03/2026 - 12:53 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Genvor Inc reported issuing 200,000 common shares held by ACT Holdings, LLC on April 15, 2026, upon conversion of $100,000 in outstanding payables owed to Dr. Yates, at a recorded transaction price of $0.50 per share. Clayton Clopton Yates, a director and ten percent owner, has voting and dispositive power over shares held by the LLC and is deemed their beneficial owner. The reported resulting holding was 600,000 shares.

Insider Trade Summary

Grant/Award: 200,000 shares

Grant/Award 1 txn

Insider Yates Clayton Clopton

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1, F2	200,000	$0.50	$100K

Holdings After Transaction: Common Stock — 600,000 shares (Indirect, ACT Holdings, LLC)

Holdings Before and After: Common Stock, 400,000 to 600,000 shares (Indirect, ACT Holdings, LLC)

Footnotes (2)

1. F1. Shares issued upon Dr. Yates' conversion of $100,000 in outstanding payables owed by the Company to Dr. Yates, pursuant to his scientific advisor agreement with the Company and the Company's restructured compensation package previously approved by the Company, which permits Dr. Yates to convert amounts due to him into Company common stock.
2. F2. Dr. Yates has voting and dispositive power with respect to shares held in the name of ACT Holdings, LLC, and is therefore deemed to be beneficial owner of shares held in its name.

Key Figures

Transaction shares: 200,000 common shares Payables converted: $100,000 Transaction price per share: $0.50 per share +1 more

4 metrics

Transaction shares 200,000 common shares Issued April 15, 2026

Payables converted $100,000 Outstanding payables owed to Dr. Yates

Transaction price per share $0.50 per share Recorded for the April 15, 2026 transaction

Resulting holding 600,000 shares Reported following the transaction

Key Terms

outstanding payables, scientific advisor agreement, voting and dispositive power, beneficial owner

4 terms

outstanding payables financial

"conversion of $100,000 in outstanding payables owed"

scientific advisor agreement technical

"pursuant to his scientific advisor agreement"

voting and dispositive power regulatory

"has voting and dispositive power with respect to shares"

beneficial owner regulatory

"deemed to be beneficial owner of shares"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many GNVR shares were issued to ACT Holdings, LLC?

Genvor reported issuing 200,000 common shares on April 15, 2026. After the transaction, the reported holding was 600,000 shares.

Why did Genvor issue shares to ACT Holdings, LLC?

The shares were issued upon Dr. Yates' conversion of $100,000 in outstanding payables owed by Genvor under his scientific advisor agreement. The company's previously approved restructured compensation package permits him to convert amounts due into common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yates Clayton Clopton

(Last) (First) (Middle)

1550 W HORIZON RIDGE PKWY

STE R #3040

(Street)

HENDERSON NEVADA 89012

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Genvor Inc [ GNVR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/15/2026		A		200,000	A	$0.5(1)	600,000	I	ACT Holdings, LLC(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares issued upon Dr. Yates' conversion of $100,000 in outstanding payables owed by the Company to Dr. Yates, pursuant to his scientific advisor agreement with the Company and the Company's restructured compensation package previously approved by the Company, which permits Dr. Yates to convert amounts due to him into Company common stock.

2. Dr. Yates has voting and dispositive power with respect to shares held in the name of ACT Holdings, LLC, and is therefore deemed to be beneficial owner of shares held in its name.

	/s/ Dr. Clayton Yates	11/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)